Compare Archer Aviation Inc (ACHR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Archer Aviation IncTrade

Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Archer Aviation Inc vs Neurocrine Biosciences Inc — how do they compare? Archer Aviation Inc trades at $6.93 (market cap $5.23B), while Neurocrine Biosciences Inc trades at $152.5 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.1× Archer Aviation Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Archer Aviation Inc nearer its low. Which is the better fit depends on your goals.

	ACHR	NBIX
Market Cap	$5.23B	$16.46B
Sector	Industrials	Health
52-Week High	$13.64	$185.50
52-Week Low	$4.44	$123.10
Enterprise Value	$3.79B	$16.48B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ACHR

Archer Aviation nears commercialization with strong growth and undervalued stock despite recent gainsSeeking Alpha · 22 hours agoBullish Archer Aviation stock jumps 11% on Boeing deal details and strong Q2 revenue growth24/7 Wall Street · 1 day agoBullish Red Cat shares jump 6.84% post-earnings despite revenue miss, driven by strong growth and sector momentum.24/7 Wall Street · 1 day agoBullish View details →

NBIX

INGREZZA shows significant quality of life and movement improvements in tardive dyskinesia patients after 24 weeks.PRNewsWire · 4 hours agoBullish View details →

About Archer Aviation Inc

Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.